Haemonetics Announces Proposed Convertible Senior Notes Offering
On May 21, 2024, Haemonetics announced its plan to offer $525 million in Convertible Senior Notes due 2029 in a private offering to qualified institutional buyers.
An additional $75 million in notes may be offered if initial purchasers exercise their option. The notes will be senior, unsecured, and accrue interest semi-annually, to be settled in cash or common stock upon conversion.
Proceeds will fund capped call transactions to offset dilution and support general corporate purposes, potentially influencing the market price of Haemonetics' stock.
- Proposed offering of $525 million in Convertible Senior Notes due 2029.
- Option to offer an additional $75 million in notes.
- Notes are senior, unsecured obligations with semi-annual interest payments.
- Net proceeds will fund capped call transactions, reducing potential stock dilution.
- Funds will support working capital and general corporate purposes.
- Potential dilution of common stock upon note conversion.
- Uncertainty in final terms of the notes, including conversion price and interest rate.
- Market price of shares may be affected by derivative transactions and capped call hedging activities.
Insights
Haemonetics' planned offering of
Interest rates and conversion terms are yet to be finalized, adding a layer of uncertainty. However, this offering potentially dilutes the existing shareholders, depending on the conversion rate and stock performance. The additional option to purchase
The proceeds will be used partly to enter capped call transactions, aimed at mitigating dilution risks. These transactions are complex financial instruments used to limit the potential dilution by setting a cap on the number of shares issued upon conversion. However, they come with their risks and costs, which investors need to consider.
In the short term, the announcement could buoy the stock price due to the optimism around the company's strategic use of funds. However, the long-term impact hinges on how effectively Haemonetics utilizes the capital for growth or debt repayment and the overall market perception of such financial maneuvers.
This initiative by Haemonetics is a classic example of a company leveraging the current low-interest-rate environment to bolster its financial health. Convertible notes are attractive to investors due to their hybrid nature, offering both the security of debt and the upside potential of equity.
Haemonetics' decision to use the raised capital for working capital and general corporate purposes, including debt repayment, should be closely monitored. Effective deployment of these funds could lead to operational improvements and reduced financial risk. Conversely, inefficient use of capital could strain the company's financials.
The capped call transactions form a noteworthy aspect of this announcement. They serve to limit potential dilution, but also involve engaging in complex derivative transactions. The effect of these hedging activities on the stock price can be significant, often causing volatility.
For retail investors, the key takeaway is the balancing act between potential short-term gains from strategic capital use and the long-term implications of increased debt and dilution. Understanding these dynamics is important for informed decision-making.
The notes will be senior, unsecured obligations of Haemonetics, will accrue interest payable semi-annually in arrears, and will mature on June 1, 2029, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. Haemonetics will settle any conversion amounts of the notes up to the
Haemonetics intends to use the net proceeds from the offering to fund the cost of entering into the capped call transactions described below and to use the remainder of the proceeds for working capital and other general corporate purposes, which may include the repayment and/or repurchase of indebtedness. If the initial purchasers exercise their option to purchase additional notes, then Haemonetics intends to use a portion of the additional net proceeds to fund the cost of entering into additional capped call transactions as described below and the remainder for working capital and other general corporate purposes.
In connection with the pricing of the notes, Haemonetics expects to enter into privately negotiated capped call transactions with certain financial institutions (the "option counterparties"). The capped call transactions are expected to cover, subject to anti-dilution adjustments substantially similar to those applicable to the notes, the number of shares of Haemonetics' common stock initially underlying the notes. If the initial purchasers exercise their option to purchase additional notes, Haemonetics expects to enter into additional capped call transactions with the option counterparties. The capped call transactions are expected generally to reduce or offset the potential dilution to Haemonetics' common stock upon any conversion of the notes and/or to offset any potential cash payments Haemonetics is required to make in excess of the principal amount of the converted notes, as the case may be, with such reduction and/or offset subject to a cap.
Haemonetics expects that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates will enter into various derivative transactions with respect to Haemonetics' common stock and/or purchase shares of Haemonetics' common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Haemonetics' common stock or the notes at that time.
In addition, Haemonetics expects the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Haemonetics' common stock and/or purchasing or selling Haemonetics' common stock or other securities of Haemonetics in secondary market transactions following the pricing of the notes and from time to time prior to the maturity of the notes (and are likely to do so following any conversion of the notes, any repurchase of the notes by us on any fundamental change repurchase date, any redemption date or any other date on which the notes are retired by Haemonetics, in each case if Haemonetics exercises its option to terminate the relevant portion of the capped call transactions, where such termination is at its option).This activity could also cause or avoid an increase or a decrease in the market price of Haemonetics' common stock or the notes, which could affect a noteholder's ability to convert the notes, and, to the extent the activity occurs during any observation period related to a conversion of the notes, it could affect the number of shares, if any, and value of the consideration that noteholders will receive upon conversion of the notes.
The notes will be sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and unless so registered, the notes and any such shares cannot be offered or sold except pursuant to an applicable exemption from, or in a transaction not subject to, such registration requirements. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of common stock issuable upon conversion of the notes, nor will there be any offer or sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.
About Haemonetics
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements, including, among other things, statements regarding the completion, timing and size of the proposed offering, the terms of the notes and the capped call transactions, the expected use of proceeds, expectations regarding actions of the option counterparties and their respective affiliates, and repurchase transactions. In addition, other written or oral statements that constitute forward-looking statements may be made by Haemonetics or on its behalf. Words such as "expect," "anticipate," "intend," "plan," "believe," "could," "should," "estimate," "may," "target," "project," or variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements represent the current expectations of Haemonetics regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are (i) the risk that the offering will not be consummated, (ii) changes as a result of market conditions, including market interest rates, (iii) fluctuations in the trading price and volatility of Haemonetics' common stock, (iv) the risk that the capped call transactions will not become effective, (v) whether and on what terms Haemonetics may repay and/or repurchase indebtedness, (vi) unanticipated uses of capital, (vii) the impact of general economic, industry or political conditions in
Investor Contacts: | |
Olga Guyette, Sr. Director-Investor Relations & Treasury | David Trenk, Manager-Investor Relations |
(781) 356-9763 | (203) 733-4987 |
Media Contact: | |
Josh Gitelson, Director-Global Communications | |
(781) 356-9776 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-announces-proposed-convertible-senior-notes-offering-302151945.html
SOURCE Haemonetics Corporation
FAQ
What is Haemonetics' proposed offering on May 21, 2024?
What are the terms for converting Haemonetics' notes?
How will Haemonetics use the proceeds from the notes offering?
What impact could the notes offering have on Haemonetics' stock price?
